Bernard Wealth Management Corp. purchased a new position in Danaher Co. (NYSE:DHR – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,419 shares of the conglomerate’s stock, valued at approximately $1,559,000. Danaher accounts for approximately 1.1% of Bernard Wealth Management Corp.’s investment portfolio, making the stock its 21st biggest holding.
A number of other institutional investors have also added to or reduced their stakes in the stock. Heck Capital Advisors LLC bought a new position in Danaher during the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. purchased a new position in Danaher in the fourth quarter worth about $31,000. Golden State Wealth Management LLC purchased a new stake in Danaher during the fourth quarter valued at approximately $31,000. Strategic Financial Concepts LLC purchased a new stake in Danaher during the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC boosted its stake in Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after buying an additional 57 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 11.10% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on DHR
Danaher Trading Down 0.6 %
NYSE DHR opened at $180.71 on Tuesday. Danaher Co. has a 12-month low of $171.92 and a 12-month high of $281.70. The company has a fifty day simple moving average of $208.60 and a two-hundred day simple moving average of $233.05. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market cap of $129.15 billion, a P/E ratio of 34.22, a P/E/G ratio of 2.66 and a beta of 0.86.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the business posted $2.09 earnings per share. On average, analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.
Danaher Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.71%. Danaher’s payout ratio is 24.24%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Alibaba Caught in Tariff Crossfire: Is It Time to Buy?
- What is the Nasdaq? Complete Overview with History
- Can Solid Biosciences Challenge Sarepta in the DMD Market?
- Using the MarketBeat Stock Split Calculator
- Will CrowdStrike’s Goodwill Strategy Pay Off in Revenue Gains?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.